Intro

Dr. Lai discusses various treatment options for different prognostic groups of AML patients, highlighting the significance of assessing fitness based on factors beyond age. Recommendations include specific chemotherapy regimens based on core binding factors, options for patients without these factors, and considerations for patients with FLT3 mutations or adverse risk factors.